PharmaTher issues letter to shareholders

PharmaTher (PHRRF) announced that Fabio Chianelli, the Company’s Founder, Chairman and Chief Executive Officer, has issued the following letter to shareholders. “We are moving swiftly into pre-launch commercialization of KETARx in the U.S. while also preparing international regulatory filings… Partnership discussions are already underway, but make no mistake-we are also advancing our commercial plan to launch KETARx this year. We have a clear and scalable sales channel targeting hospitals, specialty clinics, government institutions such as the U.S. Department of Defense and Veterans Health Administration, as well as clinical research programs and support for special or expanded access programs… Our FDA approval reinforces our mission: to unlock the full pharmaceutical potential of ketamine for mental health, neurological, and pain disorders. I am especially excited about our clinical-stage programs, which include: Parkinson’s disease, Amyotrophic Lateral Sclerosis, Complex Regional Pain Syndrome, A ketamine patch and wearable pump for diverse mental health and pain conditions. These programs fall under the FDA’s 505(b)(2) pathway, and with the current momentum in regulatory openness toward psychedelic-assisted therapies-plus potential fast-track opportunities-we believe the landscape for ketamine innovation is only improving… With your continued support, I believe we will build PharmaTher into a leader in next-generation ketamine therapeutics-creating meaningful impact for patients, expanding globally, and unlocking the full potential of ketamine. The opportunities ahead are vast, the timing is perfect, and our determination has never been stronger.”